Pain is highly prevalent, but frequently untreated or under-treated, and health care professionals are faced with a range of treatment challenges. Multimodal therapy is recommended and can be achieved using open combinations (ie, concomitant administration) of individual agents, fixed-dose combinations (FDCs), or multimodal agents (ie, single agents with multiple mechanisms of action). Co-crystallization of active pharmaceutical ingredients (APIs) offers another approach, with the potential to provide drugs with unique properties and advantages for therapeutic applications compared to combinations. API–API co-crystals are single-entity forms that offer a unique possibility of improving the physicochemical properties of both constituent APIs, as well as permitting their synchronous release. Consequently, this may positively impact on their pharmacokinetic (PK) properties and profiles, providing a potential advantage over FDCs and translating into improved clinical efficacy and safety profiles. We report here a revision of the literature concerning API–API co-crystals for the treatment of pain. It becomes apparent that identifying APIs with complementary mechanisms of action that can be adequately co-crystallized in an appropriate molecular ratio applicable for therapeutic use is challenging. In addition, API–API co-crystals normally result in a mere increased exposure of an API without defined clinical benefits (since, to maintain the benefit-risk, the dose needs to be proportionally reduced to adjust for the increased exposure). An exception to this is the co-crystal of tramadol-celecoxib (CTC), that represents a unique concept in co-crystal technology. In CTC neither of its three active components that have complementary mechanisms of action (ie, the two enantiomers of tramadol and celecoxib) show increased exposure levels versus commercially available single-entity reference products, but rather show a change in their PK profile with potential clinical advantages. CTC is in Phase III clinical development for the treatment of pain.
The B-Me-(S)-CBS catalysed borane reduction of centrosymmetric bis-N-Boc tetrahydro photodimer 3 has been achieved with virtually complete enantiotopic group selectivity (>97% ee) and in good yield (76%).
A novel approach, involving X-ray analysis of a specifically designed racemate, in combination with correlations by circular dichroism, allows the absolute configuration of the spiro lactam 4 to be determined. The outcome is that the enantiomer of this lactam which strongly inhibits uroporphyrinogen III synthase (cosynthetase) has the R-configuration and the implications of this finding are briefly discussed.
1 January 1995 in Journal of the Chemical Society, Chemical Communications
A novel X-ray analysis, combined with correlations by circular dichroism, has been used to establish the (R)-configuration at the stereocentre in that enantiomer of the spirolactam 4 which strongly inhibits uroporphyrinogen III synthase.
The structure of the iso-propanol clathrate of 4-p-hydroxyphenyl 2,2,4-trimethylthiachroman, the direct thia-analogue of Dianin's compound, has been studied by single-crystal X-ray diffraction as a function of temperature from 371 K down to 90 K. The standard Dianin unit cell, observed at high temperature, undergoes two sequential commensurate thermal phase transformations which results at low temperature in a unit cell with 16 times the original volume and with Z′(host) = 16 and Z = 288, the space group R being retained. This ultimate unit cell with a quadrupled a-axis has a = 111.7910(5) Å and c = 10.8568(1) Å and the crystal packing now features not only the prototypal [OH]6 hexamer host unit but also novel hydrogen-bonded octameric host–guest units with respective symmetries Ci and C1. In addition it has been established that the corresponding achiral selena-Dianin's clathrate and the polar chiral quasiracemic iso-propanol clathrate, space group R3, formed from R-Dianin's and S-thia-Dianin's components also exhibit novel related temperature-dependant behaviour.